Johannes Oldenburg
#125,465
Most Influential Person Now
Researcher
Johannes Oldenburg's AcademicInfluence.com Rankings
Johannes Oldenburgphysics Degrees
Physics
#4974
World Rank
#6734
Historical Rank
Biophysics
#169
World Rank
#179
Historical Rank

Download Badge
Physics
Why Is Johannes Oldenburg Influential?
(Suggest an Edit or Addition)Johannes Oldenburg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 (2004) (1140)
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors (2017) (599)
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors (2018) (391)
- Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation (1995) (350)
- The Genetic Basis of Resistance to Anticoagulants in Rodents (2005) (319)
- F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. (2012) (304)
- Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. (2013) (283)
- Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. (2006) (282)
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation (2005) (280)
- Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males (2007) (261)
- Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. (2015) (257)
- Genetic risk factors for inhibitors to factors VIII and IX (2006) (243)
- Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. (2006) (234)
- Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’ (1996) (232)
- Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). (2007) (225)
- HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII (1997) (202)
- Haemophilia A: from mutation analysis to new therapies (2005) (193)
- A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. (2019) (190)
- Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. (2013) (189)
- Inhibitor development in correlation to factor VIII genotypes (2002) (178)
- Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (176)
- Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A (2007) (175)
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A (2009) (173)
- Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. (1996) (168)
- Environmental and genetic factors influencing inhibitor development. (2004) (165)
- Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population (2006) (160)
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. (2013) (157)
- Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design (2016) (156)
- Interferon-lambda serum levels in hepatitis C. (2011) (155)
- Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. (2014) (155)
- Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. (1996) (152)
- Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (2016) (149)
- Novel mutations in the VKORC1 gene of wild rats and mice – a response to 50 years of selection pressure by warfarin? (2009) (146)
- Somatic mosaicism in hemophilia A: a fairly common event. (2001) (145)
- Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. (2003) (141)
- Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. (1991) (133)
- International Registry on Factor XIII Deficiency: A basis formed mostly on European data (2007) (129)
- VKORC1: molecular target of coumarins (2007) (125)
- A critical appraisal of one‐stage and chromogenic assays of factor VIII activity (2016) (117)
- Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. (2010) (115)
- Osteoporosis in haemophilia – an underestimated comorbidity? (2007) (114)
- The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis (2011) (113)
- Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. (2006) (110)
- Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β (2008) (109)
- Molecular basis of haemophilia A (2004) (109)
- Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference (2006) (107)
- Human Plasmacytoid Dendritic Cells Support Th17 Cell Effector Function in Response to TLR7 Ligation (2009) (107)
- Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome (1999) (107)
- Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1 (2005) (106)
- Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families Presents as a Genetic Defect of the Vitamin K-Epoxide-Reductase-Complex (2000) (106)
- Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. (2015) (101)
- Deficiencies of antithrombin, protein C and protein S – Practical experience in genetic analysis of a large patient cohort (2012) (100)
- The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. (2013) (99)
- The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. (2005) (99)
- Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment (2011) (98)
- The vitamin K cycle. (2008) (98)
- Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. (2002) (97)
- The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? (2016) (94)
- Risk factors for inhibitor development in hemophilia A. (2000) (93)
- Molecular basis of antithrombin deficiency (2011) (93)
- Human Vitamin K 2,3-Epoxide Reductase Complex Subunit 1-like 1 (VKORC1L1) Mediates Vitamin K-dependent Intracellular Antioxidant Function* (2011) (93)
- Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy (1997) (91)
- Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles (2007) (90)
- Evaluation of DHPLC in the analysis of hemophilia A. (2001) (89)
- Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. (2001) (89)
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (2017) (88)
- Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A (2016) (88)
- Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. (2020) (87)
- Results of a Screening for von Willebrand Disease Type 2N in Patients with Suspected Haemophilia A or von Willebrand Disease Type 1 (1996) (86)
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. (2019) (85)
- Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles (2011) (83)
- Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis (2020) (83)
- Acute hepatitis A in haemophiliacs (1992) (83)
- Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome (2014) (78)
- Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene (2005) (78)
- Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. (2002) (77)
- Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema (2008) (77)
- Compound heterozygous mutations in the γ‐glutamyl carboxylase gene cause combined deficiency of all vitamin K‐dependent blood coagulation factors (2004) (71)
- Profiling of active thrombin in human blood by supramolecular complexes. (2011) (71)
- A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. (2002) (71)
- Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. (2016) (71)
- Haemophilia care then, now and in the future (2009) (71)
- Protection From Type 1 Diabetes by Vitamin D Receptor Haplotypes (2006) (69)
- Defining Severity of Hemophilia: More than Factor Levels (2013) (68)
- VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding (2009) (68)
- Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs (1995) (66)
- Deep intronic ‘mutations’ cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA (2013) (66)
- Acute HIV-1 Infection in Patients with Hemophilia B Treated with β-Propiolactone-UV-lnactivated Clotting Factor (1990) (66)
- Association between Anxiety and Factors of Coagulation and Fibrinolysis (2008) (66)
- Small Deletion/Insertion Mutations within Poly-A Runs of the Factor VIII Gene Mitigate the Severe Haemophilia A Phenotype (1998) (65)
- Vitamin K-dependent coagulation factors deficiency. (2009) (63)
- Inhibitors in haemophilia: pathophysiology (2004) (62)
- Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays (2014) (61)
- Molecular mechanisms underlying hemophilia A phenotype in seven females (2009) (60)
- The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab (2019) (60)
- HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors (2017) (58)
- DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations (2015) (57)
- Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates (2005) (57)
- A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. (2009) (56)
- Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. (1992) (56)
- Genetic defects and inhibitor development in siblings with severe hemophilia (2005) (56)
- Association between phenotype and genotype in carriers of haemophilia A (2011) (55)
- Coagulation factor XIII deficiency (2014) (55)
- Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement (2017) (54)
- An update of the mutation profile of Factor 13 A and B genes. (2011) (54)
- De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism. (2000) (54)
- New Insight into the Molecular Basis of Hemophilia A (2006) (54)
- The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study (2018) (54)
- Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand (2014) (54)
- Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrate (2014) (54)
- An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. (2009) (53)
- Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. (1993) (53)
- Novel products for haemostasis – current status (2014) (52)
- European retrospective study of real‐life haemophilia treatment (2017) (52)
- Detection of large duplications within the factor VIII gene by MLPA 1 (2008) (51)
- Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). (2016) (51)
- Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates (2017) (50)
- Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe (2003) (50)
- Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype (2010) (50)
- First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study (2016) (49)
- Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. (2009) (48)
- Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection (1997) (48)
- Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial (2016) (48)
- Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates (2011) (47)
- 11 Hemophilia A Patients without Mutations in the Factor VIII Encoding Gene (2002) (47)
- Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) (2017) (46)
- Mutation Profiling in Haemophilia A (2001) (46)
- Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family (2000) (46)
- Genetic markers in acquired haemophilia (2010) (46)
- Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. (2006) (45)
- Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. (2010) (45)
- F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort (2013) (45)
- Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A (2019) (45)
- NovoSeven® in immune tolerance therapy (2000) (44)
- Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4 (2008) (43)
- Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients (2012) (43)
- Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function (2010) (43)
- Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein (1997) (42)
- A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
- Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A (2016) (42)
- High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. (2005) (42)
- Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. (2013) (42)
- The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single‐centre experience with 67 patients (2008) (42)
- SOCS1 and SOCS3 Target IRF7 Degradation To Suppress TLR7-Mediated Type I IFN Production of Human Plasmacytoid Dendritic Cells (2018) (41)
- The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH (2018) (41)
- Hepatitis A Virus Infection among the Hemophilia Population at the Bonn Hemophilia Center (1994) (40)
- Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. (2011) (39)
- Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter (2013) (39)
- Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion (2015) (39)
- Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria (2007) (39)
- Warfarin and vitamin K compete for binding to Phe55 in human VKOR (2016) (39)
- Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of Hemophiliacs (1994) (38)
- Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution. (1998) (38)
- Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay. (2013) (37)
- Characterization of duplication breakpoints in the factor VIII gene (2010) (37)
- Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study (2018) (37)
- Structure functional insights into calcium binding during the activation of coagulation factor XIII A (2019) (37)
- Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide‐based enzyme capture assay (2012) (37)
- Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants (2011) (36)
- A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3 (2007) (36)
- Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation (2006) (36)
- A new cell culture‐based assay quantifies vitamin K 2,3‐epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol‐driven VKOR assay (2013) (36)
- Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study (2020) (36)
- Factor VIII intron‐1 inversion: frequency and inhibitor prevalence (2006) (35)
- Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls (2008) (35)
- Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice (2010) (34)
- Whole Blood DNA Aberrant Methylation in Pancreatic Adenocarcinoma Shows Association with the Course of the Disease: A Pilot Study (2012) (34)
- Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data (2001) (34)
- Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence (2011) (34)
- Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs (2015) (34)
- Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome (2014) (33)
- Thrombin inhibition profiles in healthy individuals and thrombophilic patients (2012) (33)
- Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity (2015) (33)
- Elevated Interleukin-6 Concentration and Alterations of the Coagulation System Are Associated with the Development of Intraventricular Hemorrhage in Extremely Preterm Infants (2012) (33)
- Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety (2016) (33)
- Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A. (2005) (33)
- HLA genotype in patients with acquired haemophilia A (2010) (33)
- Porphyromonas gingivalis Outer Membrane Vesicles Induce Selective Tumor Necrosis Factor Tolerance in a Toll-Like Receptor 4- and mTOR-Dependent Manner (2016) (32)
- Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein (2018) (32)
- Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective (2016) (32)
- Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency (2010) (32)
- The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. (1996) (32)
- Significance of F8 missense mutations with respect to inhibitor formation (2013) (31)
- Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B (2016) (31)
- Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations. (2014) (31)
- Monitoring the progression of the in vitro selection of nucleic acid aptamers by denaturing high-performance liquid chromatography (2008) (31)
- Deletion of human GP1BB and SEPT5 is associated with Bernard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay (2011) (31)
- Methylation of L1Hs promoters is lower on the inactive X, has a tendency of being higher on autosomes in smaller genomes and shows inter-individual variability at some loci (2011) (31)
- Lack of F8 mRNA: a novel mechanism leading to hemophilia A. (2006) (31)
- Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene (2015) (30)
- Outcome after total knee arthroplasty in haemophilic patients with stiff knees (2015) (30)
- Total ankle replacement in patients with haemophilia and virus infections – a safe alternative to ankle arthrodesis? (2014) (30)
- Molecular biology of blood coagulation. (2001) (30)
- Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A (2016) (29)
- Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain. (2015) (29)
- Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans (2007) (29)
- Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site. (2016) (29)
- Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting (2019) (29)
- Bleeding diathesis in patients with mast cell activation disease (2011) (29)
- The coagulation system of extremely preterm infants: influence of perinatal risk factors on coagulation (2012) (28)
- Phenotype – genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations (2007) (27)
- Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization (2004) (27)
- In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene (2014) (27)
- Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. (2013) (27)
- Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study (2018) (26)
- Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease (2015) (26)
- ITI choice for the optimal management of inhibitor patients – from a clinical and pharmacoeconomic perspective (2014) (26)
- Long‐term outcome of total hip arthroplasty in patients with haemophilia (2017) (26)
- Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy (2010) (26)
- Perioperative management and outcome of general and abdominal surgery in hemophiliacs. (2010) (26)
- Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. (2016) (26)
- Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort (2007) (26)
- Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS) (2019) (26)
- The genetic diversification of the HIV type 1 gag p17 gene in patients infected from a common source. (1995) (26)
- Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. (2006) (26)
- The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor (2006) (26)
- Patients with familial biparental hydatidiform moles have normal methylation at imprinted genes (2005) (25)
- NOTCH4 gene polymorphisms as potential risk factors for brain arteriovenous malformation development and hemorrhagic presentation. (2017) (25)
- Comparative genetics of warfarin resistance (2013) (25)
- Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency (2009) (25)
- Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations (2014) (25)
- Faktor-XIII-Mangelerkrankungen (2014) (25)
- Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation (2010) (25)
- VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases? (2015) (25)
- Misalignment of lung vessels and alveolar capillary dysplasia (1995) (24)
- Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions (2007) (24)
- Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland (2009) (23)
- Mutations in haemophilia A (1993) (23)
- Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters (2010) (23)
- An evaluation Zequanox ® efficacy and application strategies for targeted control of zebra mussels in shallow-water habitats in lakes (2015) (22)
- Historical Review on Genetic Analysis in Hemophilia A (2014) (22)
- Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia (2012) (22)
- Large deletions identified in patients with von Willebrand disease using multiple ligation‐dependent probe amplification (2011) (22)
- Coagulation Factor IX Propeptide Mutations Causing Coumarin Hypersensitivity: Identification of Female Alanine-10 Valine Heterozygotes (2001) (22)
- Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10) (2001) (22)
- Different inactivating mutations in the LU genes of three individuals with the Lutheran‐null phenotype (2007) (22)
- TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia. (2016) (22)
- Co-activation through TLR4 and TLR9 but not TLR2 skews Treg-mediated modulation of Igs and induces IL-17 secretion in Treg:B cell co-cultures (2014) (22)
- Acute Hepatitis C in Haemophiliacs Due to “Virus-Inactivated” Clotting Factor Concentrates (1992) (21)
- Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance induction (2012) (21)
- Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A. (1993) (21)
- An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group (2012) (20)
- In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile (2013) (20)
- Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials (2017) (20)
- Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel (2020) (20)
- Detailed methylation map of LINE‐1 5′‐promoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity (2019) (20)
- Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance (2016) (20)
- Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study (2018) (19)
- NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly. (2014) (19)
- Identification of a third rearrangement at Xq28 that causes severe hemophilia A as a result of homologous recombination between inverted repeats (2012) (19)
- Transcatheter aortic valve implantation leads to a restoration of von Willebrand factor (VWF) abnormalities in patients with severe aortic stenosis - Incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI. (2017) (19)
- Genetic testing in bleeding disorders (2014) (19)
- Prophylaxis in bleeding disorders. (2011) (19)
- Founder mutation Arg485Pro led to recurrent compound heterozygous GGCX genotypes in two German patients with VKCFD type 1 (2006) (19)
- F8 genetic analysis strategies when standard approaches fail (2013) (19)
- Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia (2009) (18)
- Congenital combined deficiency of coagulation factors VII and X – different genetic mechanisms (2015) (18)
- The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif. (2014) (18)
- Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (18)
- Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function (2014) (18)
- Recombinant FXIII (rFXIII-A 2 ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency (2018) (18)
- The importance of inhibitor eradication in clinically complicated hemophilia A patients (2018) (18)
- Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study (2017) (18)
- Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations (2013) (17)
- Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies. (2019) (17)
- Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs (2019) (17)
- Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study (2016) (17)
- Three different hepatocyte transplantation techniques for enzyme deficiency disease and acute hepatic failure. (1992) (17)
- Vitamin K intake and stability of oral anticoagulant treatment (2005) (17)
- Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and association methods (2005) (17)
- Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM (2014) (17)
- DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer. (2014) (17)
- Malignant disease in the haemophilic population: moving towards a management consensus? (2012) (17)
- Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A (2020) (17)
- Unusual genomic rearrangements in introns 1 and 22 of the F8 gene (2011) (17)
- Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes (2016) (16)
- MALDI Imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy (2014) (16)
- Genomics of bleeding disorders (2014) (16)
- A Validated HPLC Method for the Determination of Vitamin K in Human Serum – First Application in a Pharmacological Study (2011) (16)
- Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study (2020) (16)
- Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines (1999) (16)
- Coagulation Factor XIIIA Subunit Missense Mutations Affect Structure and Function at the Various Steps of Factor XIII Action (2016) (16)
- Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: a retrospective study with matched pairs analysis (2013) (16)
- Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores (2016) (15)
- β-Propiolactone UV Inactivated Clotting Factor Concentrate Is the Source of HIV-Infection of 8 Hemophilia B Patients: Confirmed (1995) (15)
- Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
- Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infants (2014) (15)
- Measurements of DNA Methylation at Seven Loci in Various Tissues of CD1 Mice (2012) (15)
- Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rsI2979860 polymorphism of the IL28B gene (2011) (15)
- Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme (2016) (15)
- Tamoxifen induces resistance to activated protein C. (2014) (15)
- The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis (2008) (15)
- Parallel evolution in the V3 region of HIV type 1 after infection of hemophiliacs from a homogeneous source. (1994) (15)
- Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease (2013) (15)
- 55th Annual Meeting of the GTH (2011) (15)
- Identical point mutations in the factor VIII gene that have different clinical manifestations of hemophilia A. (1990) (15)
- Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? (1998) (14)
- Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial (2018) (14)
- Upper ankle joint prostheses in haemophilia patients (2009) (14)
- Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII (2019) (14)
- Structural Modeling Insights into Human VKORC1 Phenotypes (2015) (14)
- NLRP7, Involved in Hydatidiform Molar Pregnancy (HYDM1), Interacts with the Transcriptional Repressor ZBTB16 (2015) (14)
- Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity (2009) (14)
- Immunoadsorption in the treatment of acquired haemophilia. (2009) (14)
- Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII‐A2 (2017) (14)
- Regulation of human factor IX expression using doxycycline-inducible gene expression system (2003) (13)
- Rehabilitation of synovitis in patients with haemophilia (2007) (13)
- VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. (2018) (13)
- Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population (2017) (13)
- Association of COMT genotypes with S-COMT promoter methylation in growth-discordant monozygotic twins and healthy adults (2011) (13)
- Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program (2019) (13)
- Impact of interleukin 6 promoter polymorphisms (−174 G > C, −572 G > C and −597 G > A) on plasma IL-6 levels and their influence on the development of DVT: a study from India (2018) (13)
- Summary report of the First International Conference on inhibitors in haemophilia A. (2017) (13)
- Male-to-female transmission of HIV in a cohort of hemophiliacs — Frequency, risk factors and effect of sexual counseling (2005) (13)
- γAla82Gly represents a common fibrinogen γ-chain variant in Caucasians (2005) (13)
- Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain. (1991) (13)
- Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy (2020) (13)
- Efficient factor VIII affinity purification using a small synthetic ligand (2008) (13)
- Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. (2005) (12)
- VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation (2012) (12)
- Antibodies to factor VIII in hemophilia A patients. (2000) (12)
- Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care (2019) (12)
- Haemophilia A diagnosis by automated fluorescent DNA detection of ten factor VIII intron 13 dinucleotide repeat alleles. (1994) (12)
- Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. (1998) (12)
- F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis (2019) (12)
- Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors (2017) (12)
- Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines (2022) (12)
- Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family (2015) (12)
- Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A (2019) (12)
- Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. (2008) (12)
- gammaAla82Gly represents a common fibrinogen gamma-chain variant in Caucasians. (2005) (12)
- Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study (2013) (11)
- Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels (2019) (11)
- Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era (2018) (11)
- Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII (2006) (11)
- Structural and functional influences of coagulation factor XIII subunit B heterozygous missense mutants (2015) (11)
- Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females (2017) (11)
- Spotlight on the human factor: building a foundation for the future of haemophilia A management (2015) (11)
- Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. (2007) (10)
- Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A (2022) (10)
- Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study (2020) (10)
- Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study (2017) (10)
- The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies (2021) (10)
- Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study (2014) (10)
- The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex (2019) (10)
- Sequencing of the factor 8(F8) coding regions in 10 Turkish hemophilia A patients reveals three novel pathological mutations, and one rediagnosis of von Willebrand's disease type 2N (2006) (10)
- Successful pain treatment in arthropathic lower extremities by acupuncture in haemophilia patients (2006) (10)
- PROTECTING JUVENILE SALMONIDS FROM GULL PREDATION USING WIRE EXCLUSION BELOW HYDROELECTRIC DAMS (1995) (10)
- Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials (2018) (10)
- Modelling and expression studies of two novel mutations causing factor V deficiency (2008) (9)
- Genome-wide transcriptome induced by nickel in human monocytes. (2016) (9)
- In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. (2016) (9)
- ENDANGERED SPECIES IN THE PACIFIC ISLANDS: THE ROLE OF ANIMAL DAMAGE CONTROL (1992) (9)
- Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A (2016) (9)
- Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success (2016) (9)
- The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 gene (2008) (9)
- Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy (2008) (9)
- Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein (2013) (9)
- Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma (2018) (9)
- Molecular characterization of five Italian families with inherited severe factor XIII deficiency (2007) (9)
- High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice (2020) (9)
- Evidence of pathogenicity of a mutation in 3′ untranslated region causing mild haemophilia A (2016) (9)
- Disruption of Structural Disulfides of Coagulation FXIII-B Subunit; Functional Implications for a Rare Bleeding Disorder (2019) (9)
- Type‐3 von Willebrand disease in India—Clinical spectrum and molecular profile (2018) (9)
- Heterozygous large deletions of Factor 8 gene in females identified by multiplex PCR‐LC (2008) (9)
- In Vitro Secretion Deficits are Common Among Human Coagulation Factor XIII Subunit B Missense Mutants: Correlations with Patient Phenotypes and Molecular Models (2013) (9)
- Relative Hyperhomocysteinemia in Patients with Panic Disorder: A Case-Control Study (2010) (9)
- [Muscular compartment syndrome of the forearm in a haemophilia inhibitor patient]. (2008) (8)
- Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study (2020) (8)
- Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B (2013) (8)
- Polymorphisms in VKORC1 and GGCX are not major genetic determinants of vitamin K-dependent coagulation factor activity in Western Germans (2009) (8)
- Molecular insights and functional consequences of the interaction of heme with activated protein C. (2020) (8)
- Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder (2019) (8)
- Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers but not of Prothrombin 20210G>A Carriers. (2019) (8)
- Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene (2006) (8)
- Sequence of the rat factor VIII cDNA (2003) (8)
- Quality management and quality assurance in haemophilia care: a model at the Bonn haemophilia centre (2002) (8)
- Diversification of HIV-1 strains after infection from a unique source. (1993) (8)
- [2% Haemophilia A patients without mutation in the FVIII gene]. (2003) (8)
- Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function. (2019) (8)
- Tris(3-hydroxypropyl)phosphine is superior to dithiothreitol for in vitro assessment of vitamin K 2,3-epoxide reductase activity. (2015) (7)
- Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study (2021) (7)
- Inhibitors to Factor VIII—Molecular Basis (2007) (7)
- In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers. (2018) (7)
- Falling and fall risk in adult patients with severe haemophilia (2016) (7)
- Value and risk of laparoscopic surgery in hemophiliacs—experiences from a tertiary referral center for hemorrhagic diatheses (2014) (7)
- Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010 (2012) (7)
- Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 (2007) (7)
- SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm (2021) (7)
- Molecular genetics in haemophilia A. (2000) (7)
- Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein (2008) (7)
- A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian population (2013) (7)
- Treatment of Factor VIII Inhibitors with Selective IgG Immunoadsorption – a Single Center Experience in 50 Patients with Acquired Hemophilia* (2006) (7)
- Treatment of acute pulmonary haemorrhage in extremely preterm infants with recombinant activated factor VII (2009) (7)
- First report of a FVII-deficient Indian patient carrying double heterozygous mutations in the FVII gene. (2005) (7)
- Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. (2009) (7)
- Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
- Protamine-adsorbed magnetic nanoparticles for efficient isolation and concentration of hepatitis-C virus from human plasma samples. (2014) (7)
- Deletion of human GP 1 BB and SEPT 5 is associated with Bernard-Soulier syndrome , platelet secretion defect , polymicrogyria , and develop-mental delay (2018) (7)
- Short-term venous stasis induces fibrinolytic activation but not thrombin formation. (2014) (7)
- Capture and Release (CaR): a simplified procedure for one-tube isolation and concentration of single-stranded DNA during SELEX. (2015) (7)
- Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary (2020) (7)
- Correlation of transient elastography with APRI and FIB‐4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection (2010) (7)
- Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. (2022) (7)
- Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
- Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene (2016) (7)
- Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study (2021) (6)
- Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors (2016) (6)
- Mutational spectrum and deep intronic variants in the factor VIII gene of haemophilia A patients (2016) (6)
- The problem of novel FVIII missense mutations for haemophilia A genetic counseling (2009) (6)
- NLRP 7 , Involved in Hydatidiform Molar Pregnancy ( HYDM 1 ) , Interacts with the Transcriptional Repressor ZBTB 16 (2015) (6)
- Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation (2014) (6)
- [Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries]. (2003) (6)
- Turoctocog alfa (recombinant factor VIII) (2015) (6)
- Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations (2018) (6)
- Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers. (2020) (6)
- Recurrent intracardiac thrombosis as an unusual manifestation of inherited thrombophilia. (2007) (6)
- Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation (2005) (6)
- [Immune tolerance therapy for inhibitors in haemophilia A]. (2008) (6)
- Molecular analysis of FVIII gene in severe HA patients of Costa Rica (2010) (6)
- 11p15 DNA-methylation analysis in monozygotic twins with discordant intrauterine development due to severe twin-to-twin transfusion syndrome (2014) (6)
- Genetic Basis of Inhibitor Development in Severe Haemophilia A and B (2008) (6)
- Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study (2021) (6)
- Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study (2021) (6)
- Estimation of Nuwiq® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study (2019) (6)
- Prophylaxis in adult patients with severe haemophilia A. (2014) (6)
- Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis (2021) (6)
- Two years' experience with two recombinant factor VIII concentrates (1993) (5)
- Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies (2022) (5)
- Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study (2019) (5)
- Molecular Analysis of Fetal and Adult Primary Human Liver Sinusoidal Endothelial Cells: A Comparison to Other Endothelial Cells (2020) (5)
- Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate (2019) (5)
- Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption? (2015) (5)
- Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants (2020) (5)
- Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany (2019) (5)
- Elective total knee arthroplasty in haemophilic patients (2014) (5)
- Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia (2021) (5)
- Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy (1997) (5)
- Hemophilia A Patients with Undetectable Mutations: Current Knowledge and Future Directions* (2006) (5)
- von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention (2021) (5)
- GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients (2021) (5)
- [Impact of Preoperative Knee Stiffness on the Postoperative Outcome after Total Knee Arthroplasty in Patients with Haemophilia]. (2015) (5)
- Mutations in severe hemophilia A: distribution within the factor VIII gene, origin and influence on inhibitor development. (1997) (5)
- Development of an inhibitor-specific questionnaire for the assessment of health-related quality of life in haemophilia patients with inhibitors (INHIB-QoL) (2013) (5)
- [The national GTH haemophilia registry as database within the scope of the German human genome project]. (2003) (5)
- Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting (2017) (5)
- Characterization of the mutation spectrum in a Pakistani cohort of type 3 von Willebrand disease (2019) (5)
- Haemophilia and knee function (2009) (5)
- Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A (2019) (5)
- Acquired deficiency of coagulation factor XIII—possible evidence for a new link between coagulation and infection from a case (2013) (5)
- [Hemophiliac arthropathy of the knee joint. Gd-DTPA-enhanced MRI; clinical and roentgenological correlation]. (1994) (5)
- ▼Zoely: a new combined oral contraceptive (2014) (5)
- Influence of treatment with haemostatic agents on ETP in patients with haemophilia and VWD (2008) (5)
- [New insight in therapeutic anticoagulation by Coumarin derivatives]. (2008) (5)
- Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART (2010) (5)
- Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study (2021) (5)
- Characterisation of two novel large F8 deletions in patients with severe haemophilia A and factor VIII inhibitors (2010) (5)
- Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management (2020) (5)
- Identification of a novel factor X deletion in combination with a missense mutation in the F10 gene (2009) (5)
- ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A (2018) (5)
- Distinct Expression and Function of FcεRII in Human B Cells and Monocytes (2017) (5)
- Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural) (2020) (5)
- Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains (2019) (5)
- Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A. (2005) (4)
- Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies (2018) (4)
- New images in haemophilia (2008) (4)
- Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype (2003) (4)
- NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation (2021) (4)
- Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort (2009) (4)
- AHEAD. Advate in HaEmophilia A outcome Database. (2010) (4)
- Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania (2016) (4)
- In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies (2019) (4)
- Correction to: Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population (2017) (4)
- Novel characterization of a breakpoint in F8: an individualized approach to gene analysis when PCR and MLPA results contradict (2015) (4)
- Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII (2021) (4)
- Mild haemophilia A in a female patient with a large X‐chromosomal deletion and a missense mutation in the F8 gene – a case report (2013) (4)
- Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs (2022) (4)
- Giant haemophilic pseudotumour of the pelvis: case report and literature review (2015) (4)
- [Comprehensive Care Center Bonn from 1980 to 2009. Changes in the epidemiology and regional composition of the haemophilia population]. (2011) (4)
- [Flexion contracture in haemophilic knee arthropathy--10-year follow-up after hamstring release and dorsal capsulotomy]. (2007) (4)
- [Significance of mutation analysis in patients with haemophilia A]. (2003) (4)
- Immunoadsorption for Pregnancy‐Associated Severe Acquired Hemophilia (2014) (4)
- Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p (2020) (4)
- Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study (2016) (3)
- Selection of high affinity DNA-aptamer for activated protein C using capillary electrophoresis (2012) (3)
- Changes of static and dynamic spine alignment in patients with severe haemophilia (2021) (3)
- Methylation analysis of the promoter region and intron 1 of the factor VIII gene in haemophilia A patients (2013) (3)
- Vitamin K Epoxide Reductase Complex Subunit 1-Like 1 (VKORC1L1) Inhibition Induces a Proliferative and Pro-inflammatory Vascular Smooth Muscle Cell Phenotype (2021) (3)
- Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. (2023) (3)
- No increased bleeding risk for oral surgery in patients with severe congenital bleeding disorders due to intense perioperative management (2015) (3)
- Haemophilia A: Carrier detection by DNA analysis (1988) (3)
- Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany? (2022) (3)
- Genetic Variability of the Factor VIII Gene in the Normal Population (2005) (3)
- The European Association for Haemophilia and Allied Disorders Coagulation Factor Variant Databases (2015) (3)
- Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis (2021) (3)
- IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data (2022) (3)
- Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy (2014) (3)
- [An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment]. (2001) (3)
- [Blood coagulation and hemorrhagic diathesis]. (2006) (3)
- Haemophiliac pseudotumour: two case reports of patients with moderate haemophilia A. (2009) (3)
- [Backpain and haemophilia]. (2008) (3)
- Clinical and patient reported outcome of total ankle replacement compared to ankle fusion in end-stage heamophilic arthropathy (2020) (3)
- Molecular Profiling of Liver Sinusoidal Endothelial Cells in Comparison to Hepatocytes: Reflection on Which Cell Type Should Be the Target for Gene Therapy (2020) (3)
- Perioperative management and outcome of fracture treatment in patients with haemophilia without inhibitors (2016) (3)
- Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study (2020) (3)
- Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol (2017) (3)
- Long-term outcome of liver transplantation in HCV/HIV coinfected haemophilia patients (2014) (3)
- B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B (2018) (3)
- CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity (2022) (3)
- The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3 (2020) (3)
- Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors (2022) (3)
- An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group (2011) (3)
- Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation? (2010) (3)
- F8 gene: embedded in a region of genomic instability representing a hotspot of complex rearrangements (2015) (3)
- Treatment of Adults with Clinically Suspected Severe Thrombotic Thrombocytopenic Purpura – Experiences of a Single Centre (2007) (3)
- Splice Site Mutations Effect on the F8 mRNA Splicing (2007) (3)
- Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) (2022) (3)
- Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors (2020) (3)
- Novel point mutation in fibrinogen (Innsbruck; BβArg44Gly) (2015) (2)
- Relevance of a single dose of 270 μg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors (2009) (2)
- Molecular Genetic Analysis of a Patient with Moderate Hemophilia A and Psychomotor Developmental Delay (2013) (2)
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. (2023) (2)
- Novel findings in two patients with late‐diagnosed afibrinogenaemia: intraosseous haemorrhage and fingertip necrosis (2009) (2)
- Two de novo factor VIII gene mutations in the family of an isolated severe haemophilia A patient (2012) (2)
- Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) (2020) (2)
- VKCFD2 – from clinical phenotype to molecular mechanism (2016) (2)
- Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia (2017) (2)
- Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics (2021) (2)
- Recurrent VTE in a heterozygote of the fibrinogen Aα IVS4+1G>T and Aα p.Arg168Ter mutation (2016) (2)
- [Hemophilia A: molecular biology and carrier diagnosis]. (1994) (2)
- Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B (2018) (2)
- The EAHAD coagulation factor variant databases (2014) (2)
- Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company (2020) (2)
- Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A (2013) (2)
- Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies (2011) (2)
- Hemophilia treatment. Side effects during immune tolerance induction. (2000) (2)
- Pharmacokinetics of Azidothymidine and its Major Metabolite Glucuronylazidothymidine in Hemophiliacs Coinfected With Human Immunodeficiency Virus and Chronic Hepatitis C (1998) (2)
- [Congenital coagulopathies and coagulation factor inhibitors]. (2008) (2)
- Functional Analysis of the Factor VIII B Domain (2005) (2)
- Corrigendum to “Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay” [BBAGEN (2013) 4202–4210] (2014) (2)
- Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions (2011) (2)
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. (2023) (2)
- [Current and future prospects in haemostasis]. (2006) (2)
- A novel missense mutation in the FGB gene (p.Gly302Arg) leading to afibrinogenemia (2016) (2)
- Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation (2011) (2)
- Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections (2021) (2)
- First Case of Laparoscopic Mini-Gastric Bypass for the Treatment of Morbid Obesity in Severe Haemophilia A (2018) (2)
- Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial (2014) (2)
- Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease (2021) (2)
- Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients (2013) (2)
- The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A. (2019) (2)
- Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD (2021) (2)
- Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter (2012) (2)
- A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement (2006) (2)
- Compound heterozygosity of the protein S-gene as a cause of severe cerebral sinovenous thrombosis in a 7-year-old child. (2010) (2)
- Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation (2020) (2)
- Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 (2022) (2)
- Aptamer loaded superparamagnetic beads for selective capturing and gentle release of activated protein C (2022) (2)
- Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study (2015) (2)
- Exploring Diverse Coagulation Factor XIII Subunit Expression Datasets: A Bioinformatic Analysis (2022) (1)
- Infiltration and clustering of MHC-II+ antigen-presenting cells in the skin of patients with atopic dermatitis. (2020) (1)
- Target plasma factor levels for personalized treatment in hämophilia: a Delphi consensus statement (2017) (1)
- Clinical risk factors in the development of inhibitors in non-severe hemophilia A patients: the first results of the INSIGHT case-control study (2013) (1)
- Quantitative analysis of mRNA-expression of genes involved in the vitamin K-cycle in mouse-tissue (2009) (1)
- JAK1/2 inhibitor but not IL‐4 receptor alpha antibody suppresses allergen‐mediated activation of human basophils in vitro (2022) (1)
- Bleeding Tendency of Carriers of Hemophilia A - Dependent on the Age of the Carriers? (2005) (1)
- Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany (2023) (1)
- Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial (2019) (1)
- Site-Directed Mutagenesis of VKORC1, the Target Protein of Coumarin-Type Anticoagulants (2006) (1)
- VKORC1: the little big protein (2005) (1)
- Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis (2023) (1)
- Modified secretion of coagulation factor VIII by addition of a glycosylation site at the N terminus (2008) (1)
- Homozygosity Mapping of a Second Gene Locus for Hereditary Combined Deficiency of Vitamin K-Dependent Clotting Factors (FMFD) to Chromosome 16 (2004) (1)
- Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study (2016) (1)
- Genotype-Phenotype Correlation in Hemophilia A (2001) (1)
- Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol (2019) (1)
- FXIII Protein Inhibitor against the FXIII-A Subunit in an 8-Year-Old Boy with Inherited Severe Factor XIII Deficiency Complicated by Multiple Intracerebral Cavernomas (2020) (1)
- Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study (2021) (1)
- Quality of life in a large multinational haemophilia B cohort (The B‐Natural study) – Unmet needs remain (2022) (1)
- Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. (2023) (1)
- Clinical management and outcome after laparoscopic surgery in hemophiliacs – a matched pairs analysis (2014) (1)
- Membrane Properties of Human Induced Pluripotent Stem Cell-Derived Cultured Red Blood Cells (2022) (1)
- Real World Prospective Data on Bleeding Frequency in 1,000 Patients with Hemophilia a - is the Goal of Zero Bleeds Achievable? (2017) (1)
- Report of the Fifth Meeting of the International Network for Pediatric Hemophilia: a focus on prophylaxis and immune tolerance induction (2011) (1)
- Haemophilia B and other bleeding disorders (2000) (1)
- Genetic Background in Patients with Severe Factor XIII A-Subunit Deficiency Treated with Recombinant FXIII (2012) (1)
- FISH for Carrier Detection of large Deletions in the Factor VIII Gene (2004) (1)
- Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms (2018) (1)
- Ex Vivo Modeling of the PC (Protein C) Pathway Using Endothelial Cells and Plasma: A Personalized Approach (2022) (1)
- GGCX variants leading to biallelic deficiency to γ‐carboxylate GRP cause skin laxity in VKCFD1 patients (2021) (1)
- Recommendations for Thrombosis Prophylaxis in SARS-CoV-2 (COVID-19) (2020) (1)
- Case Report of an Acquired Inhibitor Against Factor XIII (2008) (1)
- [Gathering and evaluation of phenotype data of haemophilia A patients for correlation with genotype data]. (2003) (1)
- Individualised Prophylaxis with Recombinant Factor IX FC Fusion Protein (RFIXFC) in Adults/Adolescents With Haemophilia B: Updated Interim Results of the B-YOND Extension Study (2017) (1)
- Molecular Genetics Analysis of Von Williebrand Disease: Studies in Cohort Pakistani Patients (2015) (1)
- New insight into the function of VKORC1L1 (2010) (1)
- Molecular genetic background of haemophilia A patients with discrepancy between one-stage and two-stage factor VIII assays (2010) (1)
- Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A (2006) (1)
- Simultaneous Bilateral Total Knee Arthroplasty in Hemophilic Arthopathy (2007) (1)
- Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
- A novel fibrinogen γ chain frameshift deletion (c.637delT) in a patient with hypodysfibrinogenemia associated with thrombosis (2015) (1)
- An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII (2017) (1)
- Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study (2015) (1)
- Natural History Of Hemophilic Joint Disease Using Sensitive Imaging With Magnetic Resonance Imaging (MRI) (2013) (1)
- Real-world clinical experience of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) in comparison to conventional factor products in patients with severe hemophilia A (2021) (1)
- Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism (2022) (1)
- GGCX variants leading to biallelic deficiency to γ-carboxylate GRP cause skin laxity in VKCFD1 patients (2021) (1)
- Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study (2019) (1)
- THROMBOSIS AND HEMOSTASIS Human VKORC 1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces (2013) (1)
- Rapid and Sensitive Detection of Heterozygous Deletions of one or more Exons in Hemophilia A Females by Multiplex PCR and DHPLC Technique (2007) (1)
- Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies (2020) (1)
- Successful Embryo Transfer and Pregnancy with Donated Egg in a Female with Severe FXIII Deficiency and Climacterium Praecox (2020) (1)
- Inhibitors in PTP'S: A Retrospective Study in Germany (2006) (1)
- PC Deficiency Testing: Thrombin-Thrombomodulin as PC Activator and Aptamer-Based Enzyme Capturing Increase Diagnostic Accuracy (2021) (1)
- Epitope mapping of anti-FVIII antibodies from different sources with cellulose-bound peptide libraries (1999) (1)
- Genetic Basis for Inhibitor Development (2011) (1)
- [Algorithm for the treatment of the haemophilic arthropathia of the upper ankle joint]. (2010) (1)
- Type 2B von Willebrand Disease: Early Manifestation as Neonatal Thrombocytopenia. (2021) (1)
- Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study (2022) (1)
- Striving for a Bleed Free World - An Interim Analysis from the AHEAD Study (2016) (1)
- Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors. (2004) (1)
- A Bladder Hematoma Mimicking a Tumor in a Newborn with Severe Hemophilia A (2015) (1)
- Novel and Recurrent Mutations in the Gamma-Glutamyl Carboxylase (GGCX) Gene (2005) (1)
- Rescue and Primary ITI in Children and Adults with a Single FVIII/VWF Product (2012) (1)
- Investigation of Underlying Reasons of Factor VIII Deficiency in Hemophilia A Patients with Undetectable Mutations in the F8 Gene (2006) (1)
- Glycophorin A-based exclusion of red blood cells for flow cytometric analysis of platelet glycoprotein expression in citrated whole blood (2020) (1)
- octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment (2020) (1)
- Bleeding Symptoms in Carriers of Hemophilia A — Association to the Factor VIII Gene Mutation? (2004) (1)
- 11 novel Mutations in the Factor VIII encoding Gene lead to severe or moderate Hemophilia A (2003) (1)
- Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency (2015) (1)
- Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A (2013) (1)
- Long‐term surveillance for human anti‐murine antibodies of a group of haemophiliacs treated only with immunoaffinity‐purified FVIII concentrates (1995) (1)
- [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]. (2014) (1)
- New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency (2014) (1)
- Safety of intramuscular COVID‐19 vaccination in patients with haemophilia (2022) (1)
- Inhibitor development and management in three non-severe haemophilia A patients with T295A variant (2014) (1)
- Eahad-DB: a combined coagulation factor variant databases resource for the clinical and scientificcommunities (2015) (1)
- First Case of Compound Heterozygosity in the Gamma- Glutamyl Carboxylase Gene Causing Combined Deficiency of all Vitamin K-Dependent Blood Coagulation Factors (2004) (1)
- Molecular Genetic Analysis in Patients with Inherited Factor V Deficiency (2007) (0)
- Abstracts of the World Federation of Hemophilia, 13(th) International Musculoskeletal 2013 Congress, April 18-21, 2013, Chicago, USA. (2013) (0)
- Basel , Switzerland Calcium binding sites of coagulation factor XIII ( FXIII ) A subunit and their functional relevance to the activation of FXIII A subunit (2017) (0)
- Mutation and Inhibitor Incidence in a Defined Cohort of Severely Affected Haemophilia A Patients Born After 1977 (2000) (0)
- PLGA based nanoparticles as protein carriers: Radiolabeled protein delivery system (2017) (0)
- Transient elastography (FibroScan®) in patients with chronic hepatitis C infection and haemophilia A (2007) (0)
- VKORC1 (vitamin K epoxide recycling polypeptide), a therapeutic target for coumarin and derivatives thereof (2004) (0)
- [Hamburg Hemophilia Symposium 2012]. (2013) (0)
- Evaluation of Denaturing High Performance Liquid Chromatography (DHPLC) in the Analysis of Hemophilia A (2002) (0)
- Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene (2006) (0)
- Mutations in the Factor VIII C1 domain reducing Factor VIII binding to von Willebrand Factor and resulting in mild/moderate haemophilia A do not prevent a clinically useful response to DDAVP (2001) (0)
- Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease (2021) (0)
- Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy (2023) (0)
- Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema (2006) (0)
- Elucidation of Gross Genomic Rearrangements Involving Large Deletions in the Clotting Factor VIII Gene (2008) (0)
- Direct andIndirect Estimation oftheSexRatioofMutation Frequencies inHemophilia A (1993) (0)
- Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) (2019) (0)
- VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation (2012) (0)
- Analysis of the Biological Importance of the VKORC1 Gene via Knock-Out Mice (2008) (0)
- Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients (2016) (0)
- Abstract (2003) (0)
- PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Increased circulating levels of neurotrophins and elevated expression of their high-af fi nity receptors on skin and gut mast cells in mastocytosis (2013) (0)
- Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A (2012) (0)
- SNP Map of the Protein C Gene (2005) (0)
- Adenovirus-mediated regulatable Expression of human Factor IX in vitro and in vivo (2003) (0)
- Peripheral tolerance and lymphocyte anergy (PP-072) (2010) (0)
- Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up (2001) (0)
- Acute Care and Hospitalizations (2016) (0)
- M-FPMED01-005 (298) | Prevalence of mild factor XIII deficiencyphenotype: Current update to the WFH sponsored CRGP study (2018) (0)
- Contents Vol. 102, 2012 (2012) (0)
- Maximum foot pressure during gait in patients with severe haemophilia: A controlled cross-sectional study (2022) (0)
- Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability. (2006) (0)
- Evidence of Thrombin-Independent Generation of Activated Protein C (2016) (0)
- Identification of Novel Mutations with Molecular Modelling of Missense Mutations of Congenital Afibrinogenemia Patients in Pakistan (2015) (0)
- Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study (2010) (0)
- Contents Vol. 121, 2008 (2008) (0)
- Report on Experiences with Two Recombinant Factor VIII Concentrates: Kogenate® (Bayer) and Recombinate® (Baxter) (1995) (0)
- On the Molecular Basis of Warfarin Resistance in Rats (2007) (0)
- Factor VIII Inhibitors in Haemophilia A Patients after Continuous Infusion of Factor VIII Concentrates. (2004) (0)
- Spleen Size and Thrombocytopenia After Transcatheter Aortic Valve Implantation. (2021) (0)
- Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice (2022) (0)
- Genetic Defects in 10 Index Cases of Inherited Vitamin K Dependent Clotting Factors Deficiency (2015) (0)
- The Spectrum of Malignancies in the Era of HAART (2009) (0)
- Recombinant Expression and 3D-Modelling of C1-Inhibitor Mutants (2008) (0)
- Haemophilia care: Which outcomes should be determined in clinical routine care and are adequate for access requirements (2016) (0)
- Haemophilia (A) therapeutics: from plasma-derived products to personalized cell-based therapies (2014) (0)
- Long-range PCR screening for large rearrangements in the FVIII gene in patients without detectable mutations in the coding sequence (2010) (0)
- The Variable Clinical Expressivity of Factor V Leiden, but Not of Prothrombin G20210A, Correlates with the Extent of the APC Response to In Vivo Thrombin Formation (2018) (0)
- Osteoporosis Remains Constant in Patients with Hemophilia—Long-Term Course in Consideration of Comorbidities (2022) (0)
- VKORC1 polypeptide recycling vitamin k-epoxide, a therapeutic target of coumarin and its derivatives. (2004) (0)
- Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI) (2018) (0)
- [Homo erectus haemophilus - the haemophilic arthropathy of the leg]. (2011) (0)
- Intrauterine Subdural Hemorrhage Associated with Profound Deficiency of the Vitamin K Dependent Clotting Factors in an Infant Homozygous for a Common Polymorphism in the Vitamin K Epoxide Reductase Complex 1 (VKORC1) Promoter. (2007) (0)
- Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede (2007) (0)
- Investigation of Differential Interaction between GGCX and VKD Clotting Factors by an In Silico Approach (2022) (0)
- Pseudo tumours in haemophilia patients (2009) (0)
- Creation and Characterization of a Knock-Out Mouse for the VKORC1L1-Gene (2008) (0)
- NQO1 – A bypass of the vitamin K-cycle? (2010) (0)
- Mutation Analysis of the C1 Inhibitor Gene (2005) (0)
- Recruitment update of AHEAD (2013) (0)
- Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa (1999) (0)
- Von Willebrand Factor antigen and age explain variation in baseline FVIII: C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser) (2014) (0)
- Mitochondria: Emerging Consequential in Sickle Cell Disease (2023) (0)
- Influence of VKORC1 Haplotypes on Cardiovascular Disease (2008) (0)
- Alternative Therapy such as the Acupuncture of the Skull for Hemophilic Arthropathy (2007) (0)
- THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A (2013) (0)
- Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study (2016) (0)
- Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial (2016) (0)
- 99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry (2018) (0)
- Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany (2006) (0)
- Congenital and acquired bleeding disorders: the right factor for the right patient. (2012) (0)
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (2017) (0)
- Recurrent Intracranial Bleed in 3 Siblings: Short of a Shot of Vitamin K! (2020) (0)
- EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study (2022) (0)
- A Homozygous Deep Intronic Variant Causes Von Willebrand Factor Deficiency and Lack of Endothelial-Specific Secretory Organelles, Weibel–Palade Bodies (2022) (0)
- Patients with Familial Thrombophilia of Unknown Origin Show Low APC Response to In Vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE) (2019) (0)
- A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania (2017) (0)
- Does development of cholestatic liver disease in HIV and hepatitis C coinfected hemophiliacs indicate an unfavorable prognosis (1995) (0)
- Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis (2014) (0)
- Influence of G-CSF Mobilization and Liquid Storage Time on Post-Thaw Recovery of Lymphocyte Subpopulations and CD34+ Cells in Cryopreserved Apheresis Products (2015) (0)
- Mutation Profiling in Congenital FXIIIA Deficiency: Detection of 6 Novel Mutations (2005) (0)
- The Role of GRP and MGP in the Development of Non-Hemorrhagic VKCFD1 Phenotypes (2022) (0)
- Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population (2023) (0)
- Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain. (2009) (0)
- [Clotting factor concentrates]. (2008) (0)
- Pseudo-Homozygous APC Resistance Due to Coinheritance of Heterozygous Factor V — R506Q and Type I Deficiency Associated with Thrombosis (2008) (0)
- von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
- 1-1 Co-activation of selected knee muscles in haemophilic patients (0)
- Provision of Psychological Services in Hemophilia Treatment Postulated under the Guidelines of the WFH and the GTH—But Also in Demand? Experiences from the Hemophilia Center Bonn (2020) (0)
- Duplication breakpoints in the factor VIII gene (2010) (0)
- Structural Investigation of Two Novel Mutations in Coagulation Factor V by Molecular Modeling (2008) (0)
- The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients (2014) (0)
- Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
- Coagulation Factor XIII Mutation Profile: Update 2004 (2006) (0)
- Lithuanian Hemophilia Register: Update 2003 (2005) (0)
- First Case of Compound Heterozygous Mutations in the Kininogen Gene Causing Severe High Molecular Weight Kininogen Deficiency (2005) (0)
- 441 HCV CORE-SPECIFIC ADAPTIVE CD4+ REGULATORY T CELL CLONES IN CHRONIC HEPATITIS C ARE HIGHLY SUSCEPTIBLE TO INHIBITION BY RIBAVIRIN (2010) (0)
- Expression of the γ-Glutamyl Carboxylase (GGCX) Containing the Arg485Pro Mutation Found in two Unrelated VKCFD1 Patients (2007) (0)
- Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome. (2006) (0)
- Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study (2018) (0)
- Analysis of Factor VIII RNA from Hemophilia A Patients with no Detectable Mutation in the Coding Regions (2004) (0)
- Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis (2022) (0)
- Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting. (2006) (0)
- Annual Meeting of the Society of Thrombosis and Hemostasis Research 15-18 February 2017 Basel , Switzerland rhADAMTS 13 treatment improves ventricular remodeling and functionality after cardiac injury in mice (2017) (0)
- HLA Profile in Acquired Hemophilia (2005) (0)
- Peripheral Blood Leukocyte DNA Aberrant Methylation in Gastric Cancer Patients (2013) (0)
- Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis (2023) (0)
- Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany (2023) (0)
- S2083 Correlation of TRANSIENT ELASTOGRAPHY with APRI and Fib-4 in a Cohort of Patients with Congenital Bleeding Disorders and HCV Infection or HIV/HCV Co-Infection (2009) (0)
- Impaired in vivo activated protein C response rates indicate a thrombophilic phenotype in inherited thrombophilia (2022) (0)
- Monitoring of Emicizumab using a Two-stage chromogenic tenase platform: assay Development and Validation (2019) (0)
- Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors (2022) (0)
- Response to TLR7 Ligation Support Th17 Cell Effector Function in Human Plasmacytoid Dendritic Cells (2009) (0)
- Species-Specific Variation of VKORC1-Activity and Resistance to Warfarin (2007) (0)
- Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A (2001) (0)
- Development of Antidrug Inhibitory Antibodies against Polyethylene Glycol after Treatment with PEGylated Factor VIII Therapeutic (2022) (0)
- Immune Tolerance Induction and Immunosuppression in a 25-Year-Old Patient with Inherited Severe Factor IX Deficiency and Inhibitor: 1-Year Follow-Up (2022) (0)
- γA1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians (2006) (0)
- Erratum to: Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study (2013) (0)
- The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? (2016) (0)
- Patient-reported symptoms to predict intra-articular location of joint bleeds (2023) (0)
- Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia a Needing FVIII Treatment for Surgery - an International, Open-Label, Non-Controlled Study (NuDIMENSION) (2022) (0)
- Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study (2023) (0)
- HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany (2023) (0)
- Contents Vol. 77, 2008 (2008) (0)
- Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels (2022) (0)
- Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B (2023) (0)
- Heatmap showing p values and significant Spearman correlation coefficient (ρ) between methylation levels of different CpGs in paired peripheral blood and ductal adenocarcinoma tissues (p values of >0.05 are in white, the shown ρ-values are corresponding to p values <0.05). (2012) (0)
- In Contrast to Full-Length Factor VIII, the Calnexin (ER Chaperone) and LMAN1 (ERGIC transporter) Knockouts Have Minimal Effect on the Secretion of B-Domain-Deleted Factor VIII: Implication for Gene Therapy (2022) (0)
- Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A (2023) (0)
- Influenza infections destabilize established immune tolerance in HemA mice (2023) (0)
- Methylation Profile of Adult and Fetal FVIII Secreting Endothelial Cells in Comparison to other Endothelial Cells (2019) (0)
- Assay for ADAMTS-13 Activity with Flow Cytometric Readout (2022) (0)
- Importance of Genetic Testing in Congenital Factor VII Deficiency (2022) (0)
- Cardiovascular interventions in patients with haemophilia and severe von Willebrand disease (2008) (0)
- An improved understanding of native coagulation factor XIII complex structure using cryo-EM (2023) (0)
- Baseline Data from a 24-month Prospective, Non-interventional, Multicentre Study in Germany to Evaluate the Real-world Usage and Effectiveness of rFVIIIFc and rFIXFc in Patients with Haemophilia A or B (PREVENT) (2019) (0)
- Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders (2023) (0)
- EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis (2023) (0)
- Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP (2022) (0)
- In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia (2023) (0)
- Revealing Pathogenic Molecular Mechanism in a Type 3 von Willebrand Disease Patient by Inspecting VWF Gene Whole Intronic Region and Study of The Patient-Derived Endothelial Cells (2022) (0)
- Haemophilia A Prophylaxis with FVIII in Real-life: Snapshot Analysis on the Observational Study “Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Octanate®, Wilate® or Nuwiq® - NIS Previq” (2019) (0)
- Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH) (2023) (0)
- A Retrospective Study on the Development of Inhibitors after Continuous Infusion of Factor VIII (2004) (0)
- HIV-associated microbial translocation may affect cytokine production of CD56bright NK cells via stimulation of monocytes. (2022) (0)
- Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study (2022) (0)
- Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study (2022) (0)
- Anti-drug antibodies against the PEG moiety inhibit the procoagulant activity of therapeutic PEGylated FVIII. (2023) (0)
- Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain (2005) (0)
- Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency (2018) (0)
- This information is current as in Human B Cells and Monocytes RII ε Distinct Expression and Function of Fc Garbi (2017) (0)
- Founder Effect of the Factor-IX-Propeptide-Val-10 Variant Is Responsible for Most Marcumar-lnduced Severe Haemophilia B Cases During Oral Anticoagulant Therapy — Consequences for Monitoring (1999) (0)
- Recombinant expression of wildtype and mutated γ-glutamyl carboxylase (2008) (0)
- Molecular Characterization of F8 Secreting Cell (2015) (0)
- [HIV-associated parotid cysts]. (1994) (0)
- Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII (2023) (0)
- Novel Gamma-Glutamyl Carboxylase Mutation Causing Hemorrhagic and Non-Hemorrhagic VKCFD1 Phenotypes (2022) (0)
- Inversions at Xq28 Causing Hemophilia A Are Associated with Specific (2020) (0)
- Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
- interfaces 4-hydroxycoumarin resistance and affect putative warfarin binding Human VKORC1 mutations cause variable degrees of (2013) (0)
- Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study (2022) (0)
- Types and Sub Types of Von Willebrand Disease Classified on the Basis of Multimer Analysis (2015) (0)
- Alpha-2 Macroglobulin: A Novel Putative Interacting Partner of FXIII/FXIIIB Subunit? (2020) (0)
- Functional Promoter Polymorphism in the VKORC1 Gene is no Major Genetic Determinant for Vitamin K Dependent Coagulation Factor Activity (2008) (0)
- Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY) (2021) (0)
- Advances in HIV-PCR in respect to the different fields of diagnosis (1994) (0)
- A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates (2023) (0)
- 624 HEPATITIS C VIRUS INFECTION ALTERS SERUM LEVELS OF THE MAJOR TYPE III INTERFERON IL-29 (2008) (0)
- Structural Characterization of Factor VIII B Domain to Generate an All Atom Full-Length Structure of the Coagulation Factor VIII Protein (2022) (0)
- Detection of parvovirus B19 specific antibodies and DNa in sera of hemophiliacs (1994) (0)
- Impact of Novel Missense Mutation (p. Arg510Cys) in the FGA Gene Resulting in Dysfibrinogenemia (2020) (0)
- as a somatic mosaicism De novo factor VIII gene intron 22 inversion in a female carrier presents (2013) (0)
- Stratifying Cumulus Cell Samples Based on Molecular Profiling to Help Resolve Biomarker Discrepancies and to Predict Oocyte Developmental Competence (2021) (0)
- Clinical presentation of inhibitor development in non-severe hemophilia A: Half of patients have high titer inhibitors and present with bleeding complications (2014) (0)
- A Polycistronic Mammalian Vector/Expression System to Establish the Causality of FXIII Heterozygous Variant Species (2022) (0)
- XIII deficiency Recombinant factor XIII: a safe, and novel treatment for congenital factor (2012) (0)
- GENETIC BASIS OF ACQUIRED HAEMOPHILIA (2007) (0)
- Gene Therapy for Hemophilia-Opportunities and Risks. (2022) (0)
- LumiTope: Toward Improving the Performance of Identification of Antifactor VIII Antibodies in Congenital and Acquired Hemophilia A (2020) (0)
- Region critical for monocytotropism is concerned in diversification of HIV-1 strains derived from a unique infectious source (1994) (0)
- Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type (2018) (0)
- Genetics of warfarin resistance Two enzymes essential for the vitamin K cycle (2017) (0)
- Variability in Clinical Phenotype of Hemophilia : Role of the F 8 / F 9 Genotype (2013) (0)
- Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo (2023) (0)
- F8a, F8b and F8c expression and its association with 3 SNPs within the F8 gene in healthy controls and HA patients with no mutation (2010) (0)
- Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency (2005) (0)
- nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene ( (2014) (0)
- Hepatitis C Virus Infektion verändert Serumspiegel des Typ III Interferons IL-29 (2008) (0)
- Experiences in Routine Genetic Analysis of Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders. (2022) (0)
- Longterm follow-up of a women with an acquired inhibitor against factor VIII (2010) (0)
- Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII (2014) (0)
- Perception of Actual Factor Concentrates and Expectations Towards Future Treatment with New Long-Lasting Products - Results of a Survey Among Haemophilia Patients in Germany (2015) (0)
- Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing (2023) (0)
- Localization and characterization of human anti-factor VIII antibody epitopes by screening cellulose-bound peptide libraries (2000) (0)
- Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy (2023) (0)
- Association analysis between DNA methylation from total blood and polymorphisms in DNA methyltransferase (DNMT) genes in healthy individuals: A tendency toward higher methylation levels in males (2008) (0)
- Erratum (2020) (0)
- Switching to rVIII-SingleChain Ensures Bleeding Protection and may Reduce Injection Frequency or Consumption in Hemophilia A Patients: Real-world Clinical Experience in Adults/Adolescents and Pediatric Patients (2019) (0)
- A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group (2021) (0)
- VKORC1 (vitamin K epoxide tilbageføringspolypeptid), a therapeutic target of coumarin and its derivatives (2004) (0)
- Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A (2022) (0)
- Haemophilia A in a Female Due to Compound Heterozygosity of a Maternally Inherited Point Mutation and a Paternally De Novo Large Deletion Within the Factor VIII Gene (2000) (0)
- Frequency and Inhibitor Risk of the Intron-1-Inversion Mutation in the German Hemophilia Population (2005) (0)
- AHEAD International and German Studies: Effectiveness, Safety, and Quality of Life Outcomes in Patients with Hemophilia A Treated with Antihemophilic Factor (Recombinant) in a Real-World Setting Over 5 Years (2020) (0)
- Various Missense Mutations in the Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Cause Hereditary Coumarin Resistance (2007) (0)
- Real life management of children with severe hemophilia A and inhibitors: First results of the remain study (2016) (0)
- In Vivo-Assay for Warfarin-Resistance by Coexpression of VKORC1 and Vitamin K-Dependent Coagulation Factors (2007) (0)
- 882 SELECTIVE INDUCTION OF ADAPTIVE REGULATROY T-CELLS IN CHRONIC HEPATITIS C (2009) (0)
- Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region (2016) (0)
- Missense Mutations at ALA-10 in the Factor IX Propeptide: A Novel Mechanism for Severe Bleeding During Oral Anticoagulant Therapy (1998) (0)
- Bleeding Tendency in Factor XI Deficiency: Report on two Families and the Detection of a Novel Mutation within the Factor XI Gene (2005) (0)
- Antioxidant properties of VKORC1L1 (2009) (0)
- Determination of ɣ-carboxylation Pattern of Different Vitamin K Dependent Proteins with Respect to VKCFD1 Phenotype (2019) (0)
- Coincidence of 2 Severe Chronic Diseases: Presymptomatic Diagnosis of Wilson Disease in A Boy With Severe Haemophilia A (2013) (0)
- Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq®, Octanate® or Wilate® — the Protect-NOW Study (2018) (0)
- Inhibitor development and FVIII gene mutation analysis in a pediatric cohort treated with sucrose formulated, full‐length recombinant Factor VIII (2002) (0)
- Dynamic of Thrombin Generation in Patients with Severe Hemophilia A (2008) (0)
- How to avoid being eaten: a lymphoma's defense (2017) (0)
- Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo (2023) (0)
- Expression Analysis of C1-Inhibitor Mutants Confirms Causality of Missense Mutations for Hereditary Angioedema (2007) (0)
- Subject Index Vol. 77, 2008 (2008) (0)
- Subject Index Vol. 23, 1996 (1996) (0)
- De Novo Factor VIII Intron 22 Inversion in Early Embryogenesis Leads to a Mosaic Genotype in Leukocyte and Fibroblast Cells (2000) (0)
- Erratum: A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group (2021) (0)
- State-of-the-Art in Hämostaseologie (2011) (0)
- Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families: Evidence for a Defective Vitamin K-Epoxide-Reductase Complex (2001) (0)
- Correction: Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles (2015) (0)
- Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A (2021) (0)
- Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A (2006) (0)
- Suspected vitamin K-dependent coagulation factor deficiency in pregnancy: A case report (2022) (0)
- UNCHANGED PHARMACOKINETICS OF AZIDOTHYMIDIN (AZT) IN HIV-INFECTED HEMOPHILIACS WITH CONCOMITANT CHRONIC HEPATITIS (1994) (0)
- Establishment of an International Registry of Patients with Congenital FXIII Deficiency (2007) (0)
- Quantitative expression analysis of the F8 mRNA in haemophilia A patients with no detectable mutation in the F8 gene (2009) (0)
- Five Novel Mutations in F13B Gene Resulting in Mild FXIII Deficiency (2007) (0)
- Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond (2022) (0)
- High Levels of Human Factor IX Transgene Expression in Mice Increase Blood Procoagulant Activity (2008) (0)
- Novel Variants in VKORC1 — the Target Protein of Cumarin-Type Anticoagulants — in Rodents from Warfarin-Resistance Areas in Europe, Asia and America (2008) (0)
- VKORC1 (vitamin K epoxide feed back polypeptide), a therapeutic target of coumarin and its derivatives (2004) (0)
- PSEUDO-HOMOZYGOUS APC RESISTANCE DUE TO COINHERITANCE OF HETEROZYGOUS FACTOR V-R506Q AND FV TYPE I DEFICIENCY (2007) (0)
- Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A (2016) (0)
- Resistance to Coumarin in a 55-year-old Patient with Chronic Arrhythmia (2005) (0)
- Molecular Profiling of Fetal and Adult Liver Sinusoidal Endothelial Cells: A F8 Secreting Cell (2020) (0)
- Expressing Recombinant Coagulation Factors in Yeast and Insect Cells (2005) (0)
- Coexpression of VKORC1 and coagulation factor IX (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Johannes Oldenburg?
Johannes Oldenburg is affiliated with the following schools: